Skip to main content
. Author manuscript; available in PMC: 2014 Apr 15.
Published in final edited form as: Biochem Pharmacol. 2013 Feb 5;85(8):1066–1076. doi: 10.1016/j.bcp.2013.01.026

Figure 2.

Figure 2

Effect of silymarin on UVB-induced suppression of CHS response and DNA damage in XPA-deficient mice. (A), Topical treatment of XPA-deficient mice with silymarin does not improve the ability of DCs to induce CHS in naïve mice. Donor mice (XPA-deficient) were treated with or without silymarin and CD11c+ cells from lymph nodes were positively selected using MACS system as described in Materials and methods. Recipient mice (C3H/HeN) were injected subcutaneously with 5× 105 CD11c+ cells obtained from donor mice (XPA-deficient). Recipient mice were ear challenged with DNFB 5 days after injection of cells, and ear skin thickness was measured before and 24 h after challenge. The change in ear thickness is reported as the mean of millimeters (× 10-2) ± SD, n=5 per group. *No significantly greater CHS response in silymarin treated mice versus recipient of CD11c+ from UVB plus DNFB treated mice. Significantly lower CHS response versus the positive control (DNFB-sensitized) group, P<0.001. (B), Analysis of CPDs by dot-blot assay. Silymarin does not stimulate repair of UVB-induced DNA damage in BM-DCs obtained from XPA-deficient mice. Results are shown from a single experiment that is representative of two independent assays.